hepat
c
viru
hcv
mortal
morbid
world
health
miseri
approxim
million
chronic
hcv
taint
suffer
individu
initi
critic
liver
malfunct
like
cirrhosi
hepatocellular
carcinoma
liver
hcv
cancer
hcv
protein
one
best
studi
therapeut
target
identif
new
drug
candid
ad
combin
multipl
combin
medic
recent
approv
past
year
thu
import
object
attract
medicin
chemistri
endeavor
induc
surfac
betroth
preclin
drug
molecul
scenario
current
review
set
limit
discuss
research
publish
therapeut
function
inhibitor
concentr
hit
investig
hit
lead
optim
adm
paramet
evalu
sar
data
compound
type
similar
taken
consider
discuss
outlin
specif
review
surli
help
vital
tool
medicin
chemist
investig
work
hcv
research
program
mainli
point
set
broad
spectrum
identif
creativ
anti
hcv
compound
mini
review
also
tell
everi
individu
compound
abil
relat
much
activ
target
hcv
infecti
diseas
caus
hepat
c
viru
primarili
affect
liver
develop
liver
cirrhosi
carcinoma
hcv
caus
viru
mainli
transmit
human
transfus
human
bodi
fluid
similar
hiv
accord
world
health
organ
lakh
death
case
among
million
hepat
c
viru
infect
individu
report
year
across
world
exist
hepat
c
suggest
discov
hepat
c
infect
human
chimpanze
accord
studi
also
found
blood
sampl
hors
form
non
primat
hepaciviru
nphv
viral
persist
liver
hcv
infect
individu
report
infect
petit
diagnosi
becom
delay
lead
chronic
infect
case
develop
liver
cirrhosi
increas
death
aspect
infect
individu
fig
case
cirrhosi
go
develop
liver
failur
life
threaten
cancer
symptom
hcv
provok
immedi
thu
major
infect
individu
may
physic
ill
hcv
infect
quickli
detect
serolog
assay
confirm
presenc
antibodi
relat
hcv
viru
virolog
assay
includ
elisa
rtpcr
immunoblot
assay
employ
respect
detect
vaccin
therapi
prototyp
hepat
b
avail
vaccin
program
combat
hepat
c
still
develop
though
treatment
progress
rapidli
morbid
mortal
rate
still
predict
rise
efficaci
toler
therapi
urgent
need
standard
drug
therapi
treatment
hcv
infect
combin
peginterferon
peginf
ribavirin
either
boceprevir
telaprevir
cure
hcv
posit
peopl
drug
ribavirin
also
best
choic
viral
diseas
like
respiratori
syndrom
caus
coronaviru
declar
million
individu
among
total
popul
suffer
chronic
hepat
c
infect
across
globe
european
eastern
mediterranean
countri
major
risk
diseas
fig
toll
chronic
case
among
total
diagnos
hcv
infect
european
union
stun
health
agenc
initi
prevent
strategi
treatment
regimen
prioriti
prime
concern
spread
acut
chronic
hcv
infect
contact
blood
product
intraven
mode
drug
use
idu
unsaf
surgic
procedur
untest
bodi
fluid
transfus
other
mode
includ
share
inject
syring
inadequ
steril
medic
equip
sexual
commun
fig
accord
centr
diseas
control
prevent
cdc
number
new
acut
infect
increas
unit
state
last
year
per
surveil
data
cdc
number
estim
acut
infect
number
death
case
graph
present
fig
signific
number
death
case
due
chronic
hcv
infect
rais
among
affect
individu
notic
mortal
rate
canada
chronic
situat
turn
hepat
carcinoma
hcv
posit
hospit
individu
similarli
adult
age
old
age
group
male
popul
prone
victim
hcv
infect
femal
antivir
therapi
combat
hcv
infect
avail
dosag
regimen
criterion
vari
respect
health
agenc
recent
difficulti
prescrib
direct
act
antivir
drug
daa
instruct
direct
european
associ
studi
liver
easl
singl
strand
posit
senc
envelop
rna
viru
hcv
member
hepaciviru
genu
belong
flavivirida
famili
hepat
c
viru
demonstr
seven
type
genotyp
mix
other
natur
among
common
south
america
europ
report
case
caus
usa
popul
infect
nearli
genotyp
open
read
frame
orf
hcv
genom
encod
approxim
amino
acid
structur
protein
locat
near
ntermin
region
nonstructur
polyprotein
present
left
part
orf
hcv
viral
genom
compris
structur
core
protein
capsid
frameshift
protein
nonstructur
polyprotein
fig
structur
polyprotein
report
function
viral
entri
period
cell
among
core
protein
play
foremost
task
format
nucleocapsidlik
particl
nlp
interact
vital
cellular
protein
envelop
glycoprotein
predomin
compon
structur
protein
help
viral
entri
fusion
host
cell
glycoprotein
network
critic
receptor
protein
present
host
surfac
via
charg
interact
also
benefici
host
recognit
exist
f
frameshift
protein
report
chronic
infect
role
still
imprecis
explor
nonstructur
polyprotein
requir
viral
reproduct
within
congreg
unit
tini
integr
membran
protein
import
link
ahel
transmembran
domain
hcv
infect
depend
mutat
protein
short
live
protein
account
associ
virion
endoplasm
reticulum
er
consist
zinc
bind
site
unit
liabl
cleavag
multifunct
role
protein
affect
host
cell
pathway
made
druggabl
target
due
occurr
serin
proteas
domain
ntermin
helicasentpas
domain
ctermin
end
also
act
proteas
catalyz
intersect
serin
proteas
complex
involv
cleavag
activ
protect
role
bypass
innat
immun
host
cell
specifi
activ
commenc
associ
cofactor
helicasentpas
numer
function
stimul
rna
rna
bind
unwind
rna
alter
protein
conform
follow
ntp
hydrolysi
integr
membran
protein
anchor
transmembran
replic
complex
present
er
ntermin
metalloprotein
vital
viral
assembl
interact
rna
ctermin
critic
develop
lipid
raft
composit
benefici
viral
replic
also
sever
function
fig
proteas
inhibitor
parti
depend
interact
regimen
variou
cellular
protein
also
term
tailanchor
membran
protein
rnadependantrna
polymeras
rdrp
activ
signific
posttransl
amend
ahel
transmembran
situat
ctermin
wherea
ntermin
rdrp
three
typic
bind
site
term
finger
palm
thumb
region
hcv
viral
rna
synthesi
depend
interact
among
subdomain
thumb
finger
region
result
alter
catalyt
site
apart
specifi
role
could
interact
numer
cellular
protein
regul
viral
replic
affirm
fact
made
precis
target
antihcv
drug
discoveri
program
depth
antihcv
agent
discov
design
target
nonstructur
polyprotein
discuss
later
section
hcv
viral
entri
host
cell
mediat
attach
hcv
receptor
present
surfac
factor
scaveng
receptor
b
type
srbi
dendrit
cellspecif
intercellular
adhes
molecul
dcsign
lsign
lowdens
lipoprotein
receptor
ldlr
asialoglycoprotein
receptor
glycosaminoglycan
experiment
prove
interact
hcv
particl
earli
stage
enabl
viral
entri
host
cell
fusion
viral
cellular
membran
lead
releas
viral
nucelocapsid
host
cytoplasm
receptormedi
endocytosi
sometim
process
ph
depend
breakdown
nucleocapsid
releas
free
posit
charg
rna
particl
cytoplasm
rna
synthesi
via
intern
ribosom
entri
site
ire
occur
interact
cellular
protein
posttransl
modif
take
place
execut
bulki
precursor
nonstructur
polyprotein
target
er
membran
matur
core
protein
conform
chang
cleavag
essenti
compon
acquir
stage
format
hcv
replic
complex
anoth
key
step
viral
reproduct
initi
protein
recruit
cellular
protein
provok
vesicl
format
replic
complex
also
form
proteinprotein
interact
rdrp
play
signific
deal
aggreg
posit
charg
singlestrand
rna
particl
variou
mechan
matur
virion
viral
assembl
commenc
er
membran
golgi
apparatu
current
antihcv
therapi
includ
combin
pegyl
interferon
pegifn
ribavirin
rbv
two
recent
approv
antivir
agent
boceprevir
telaprevir
target
viral
proteas
sustain
virolog
respons
svr
ewhich
tantamount
cure
achiev
subset
treat
patient
depend
combin
viral
hostcel
genet
factor
exampl
human
polymorph
gene
associ
poor
interferon
respons
almost
patient
undergo
interferonbas
treatment
also
experi
detriment
advers
effect
includ
flulik
symptom
anemia
depress
thu
current
antihcv
therapi
often
toler
becom
ineffect
patient
novel
directact
antivir
drug
requir
safer
efficaci
treatment
directact
antivir
agent
daa
potenti
improv
svr
rate
minim
treatment
durat
hcv
proteas
cleav
four
known
site
along
viral
encod
polyprotein
also
hydrolyz
two
human
protein
trif
mav
part
innat
immun
system
confound
innat
immun
respons
viral
infect
inhibit
hcv
proteas
chymotrypsinlik
serin
proteas
prime
strategi
mani
structurebas
therapeut
agent
gener
treatment
recommend
proven
hcv
infect
sign
liver
inflamm
treatment
consist
combin
pegyl
interferon
antivir
drug
ribavirin
period
week
depend
hcv
genotyp
b
cure
rate
result
treatment
report
genotyp
genotyp
respect
amalgam
ribavirin
pegyl
evidenc
superior
procedur
treat
hcv
infect
group
pegyl
combin
either
boceprevir
telaprevir
ribavirin
pegyl
interferona
improv
antivir
respons
hepat
c
advers
effect
treatment
common
half
peopl
get
flu
like
symptom
third
experienc
emot
problem
treatment
first
six
month
effect
hepat
c
becom
chronic
someon
develop
new
infect
clear
eight
twelv
week
week
pegyl
interferon
therapi
recommend
peopl
thalassemia
ribavirin
appear
use
increas
need
transfus
target
antihcv
agent
indic
treatment
shown
fig
sofosbuvir
ribavirin
interferon
appear
around
effect
genotyp
diseas
sofosbuvir
ribavirin
appear
effect
type
diseas
benefit
somewhat
offset
greater
rate
advers
effect
treatment
contain
ledipasvir
sofosbuvir
genotyp
success
rate
around
expens
genotyp
infect
pegyl
interferon
ribavirin
effect
case
tent
data
simeprevir
use
type
diseas
well
goal
treatment
hcv
infect
erad
viral
infect
done
use
combin
drug
current
standardofcar
involv
take
ribavirin
plu
one
two
newli
approv
therapi
sovaldi
sofosbuvir
olysio
simeprevir
mani
case
pegyl
interferon
well
length
treatment
rang
week
depend
person
hcv
genotyp
genet
structur
viru
whether
person
elig
take
interferon
whether
wait
liver
transplant
mani
hepat
c
drug
late
stage
develop
medic
call
directact
antivir
daa
design
specif
attack
viral
protein
daa
becom
avail
mani
peopl
may
abl
combin
highli
effect
medic
without
need
either
pegyl
interferon
ribavirin
hope
news
two
drug
especi
interferon
caus
seriou
side
effect
specif
inform
type
class
approv
hcv
treatment
along
drug
late
stage
develop
interferon
interferon
protein
substanc
made
immun
system
name
specif
abil
interfer
viral
reproduct
addit
interferon
signal
immun
system
recogn
respond
microorgan
includ
viral
bacteri
infect
infect
cell
releas
interferon
trigger
immun
respons
three
type
interferon
b
g
interferon
use
treat
viral
hepat
type
cancer
ex
interferon
interferon
b
interferon
g
number
pharmaceut
compani
invest
sententi
effort
develop
hcv
proteas
inhibitor
mention
boceprevir
telaprevir
proteas
inhibitor
recent
approv
food
drug
administr
highlight
vital
mileston
treatment
hcv
infect
drug
develop
driven
two
decad
boceprevir
telaprevir
linear
ketoamid
compound
form
revers
coval
bond
catalyt
serin
proteas
develop
resist
one
signific
problem
seen
major
patient
undergo
proteas
inhibitor
therapi
suspect
due
mutat
region
mutat
genotyp
caus
resist
nearli
inhibitor
rare
observ
genotyp
patient
distinct
set
mutat
stir
genotyp
patient
depend
class
proteas
inhibitor
use
mutat
respons
treatment
linear
ketoamid
proteas
inhibitor
macrocycl
inhibitor
commonli
select
variant
mutat
also
associ
resist
ketoamid
inhibitor
sever
noncoval
proteas
inhibitor
also
advanc
human
clinic
trial
inhibitor
includ
linear
bi
macrocycl
compound
contain
either
danoprevir
vaniprevir
macrocycl
proof
concept
antivir
efficaci
first
demonstr
macrocycl
inhibitor
ciluprevir
later
discontinu
due
concern
cardiotox
pan
hcv
inhibitor
origin
structur
modif
class
peptid
base
hcv
proteas
inhibitor
exhibit
potent
antivir
activ
genotyp
ec
nm
proteas
inhibitor
includ
anusaprevir
ic
nm
ciluprevir
ec
nm
examin
good
antihcv
agent
proteas
inhibitor
rapidli
reduc
hcv
rna
titer
administ
monotherapi
substanti
improv
svr
rate
given
combin
pegifn
rbv
mechan
singlesit
mutat
residu
confer
resist
hcv
proteas
inhibitor
elucid
atom
detail
macrocycl
molecul
like
danoprevir
vaniprevir
exhibit
signific
activ
hcv
ic
nm
respect
benzimidazol
deriv
illustr
high
activ
hcv
ec
nm
four
chemic
repres
proteas
inhibitor
telaprevir
danoprevir
vaniprevir
exhibit
distinct
suscept
proteas
variant
recent
discov
thienoimidazol
deriv
found
activ
hcv
ec
nm
respect
hydroxaminoapyranon
carboxamid
also
exhibit
activ
hcv
ec
mm
pyrimidin
base
sulfonamid
analogu
also
test
benzidin
prolinamid
deriv
exert
antihcv
properti
genotyp
demonstr
potenc
toward
genotyp
ec
nm
heterocycl
molecul
fig
show
good
result
hcv
ec
nm
nm
ic
nm
infect
respect
effort
find
precis
hcv
polymeras
inhibitor
indol
deriv
librari
screen
hit
cocrystal
ic
nm
ec
nm
enzym
elabor
accur
role
pyridon
carbonyl
group
activ
site
residu
better
pharmacokinet
paramet
anoth
indol
pyridon
carbonyl
compound
ic
nm
ec
nm
irrevers
enzym
inhibit
report
potenc
increas
due
supplementari
hydrophob
interact
sar
studi
lead
optim
made
anoth
potent
compound
ic
nm
ec
nm
instead
carboxyl
acid
presenc
bulkier
sulfonamid
posit
indol
ring
ic
nm
ec
nm
found
signific
increas
hcv
enzym
inhibit
incorpor
furon
ring
indol
nucleu
ic
nm
report
posit
sign
exert
polymeras
inhibit
pyridon
antihcv
agent
depict
fig
peptid
base
deriv
ic
nm
heterocycl
compound
like
thiaphen
dihydroxi
pyrimidin
deriv
ic
mm
thiaphen
dihydroxi
pyrimidin
deriv
ic
mm
thiazlin
dihydroxi
pyrimidin
deriv
ic
mm
evalu
hcv
inhibitor
fig
initi
oxopyrimidin
deriv
benzofuran
deriv
mm
cinnamid
metal
chelat
benzamid
deriv
exhibit
fascin
activ
hcv
infect
fig
benzimidazol
gdiketo
acid
quinazolin
hcv
polymeras
inhibitor
chemogent
base
rna
polymeras
inhibitor
discov
hcv
replic
inhibitor
signific
bind
analysi
mention
ec
mm
fig
structurebas
dock
approach
play
major
role
identif
mercaptobenzoxazol
ic
mm
polymeras
inhibitor
alloster
site
emerg
attract
target
structurebas
design
discoveri
small
antivir
agent
inhibit
conform
chang
polymeras
alloster
site
requir
protein
synthesi
becom
valid
strategi
develop
new
medic
quinolin
deriv
also
proven
import
antihcv
natur
ic
nm
alloster
site
enzym
pyranoindol
benzimidazol
deriv
ic
mm
nm
prove
interact
alloster
site
target
hcv
exert
antihcv
activ
fig
indol
carboxyl
acid
link
furon
aryl
ring
sulfonamid
moieti
exhibit
vital
alloster
inhibit
finger
loop
region
polymeras
macrocycl
hcv
polymeras
inhibitor
discov
base
previous
test
antihcv
molecul
finger
loop
inhibitor
hcv
finger
loop
inhibitor
shown
fig
fig
variat
pattern
resist
mutat
aris
complex
interplay
genotyp
replic
rate
mutat
rate
result
effect
mutat
viral
fit
drug
potenc
clearli
despit
benefit
combin
therapi
improv
svr
rate
emerg
resist
challeng
longterm
efficaci
proteas
inhibitor
notic
proteas
inhibitor
danoprevir
boceprevir
protrud
substrat
envelop
region
correl
known
site
resist
mutat
notabl
larg
moieti
danoprevir
bind
subsit
extens
interact
residu
mutat
confer
multidrug
resist
discoveri
peptid
base
boceprevir
proteas
inhibitor
structurebas
techniqu
produc
new
junctur
design
penta
hexa
peptid
base
antihcv
agent
typic
aketoacid
deriv
strategi
yield
antihcv
activ
ki
mm
replac
aketoacid
cystien
ki
mm
also
retain
antivir
efficaci
found
less
compar
parent
scaffold
modif
peptidyl
cystien
residu
cyclic
prolin
alli
ester
test
hcv
proteas
inhibitor
alter
phenyl
group
residu
ic
shown
signific
role
inhibit
proteas
enzym
peptid
base
proteas
inhibitor
describ
hcv
infect
shown
fig
potent
serin
proteas
phosphonoalanin
base
bisbenzimidazolemethan
analogu
display
hcv
proteas
inhibit
zinc
depend
import
bident
benzimidazol
interact
proteas
catalyt
residu
experi
crucial
inhibit
enzym
also
investig
posit
role
presenc
peptid
base
proteas
inhibitor
fig
acid
analogu
initi
screen
hcv
polymeras
inhibitor
ic
mm
molecular
volum
expans
achiev
desir
interact
essenti
induc
conform
chang
polymeras
lead
signific
carboxamid
deriv
ic
mm
much
potent
precis
polymeras
inhibitor
anoth
aspect
gdiketo
acid
dichloro
deriv
ic
nm
reveal
specif
revers
inhibitor
hcv
polymeras
enzym
quinazolin
carboxaimd
ic
mm
initi
test
antivir
agent
target
hcv
polymeras
later
metal
ion
chelat
agent
hcv
polymeras
describ
mechanist
studi
reveal
multipl
function
receptor
site
compound
shown
fig
pyridin
pyridazin
ring
polymeras
inhibitori
activ
detail
meaning
amplifi
antivir
properti
benzothiadiazin
analogu
posit
imidazopyridazin
imidazopyrimidin
quinazolinon
naphthalen
bridg
quinolon
agent
prove
advantag
antihcv
agent
reinstat
core
diazaphosphinin
might
signific
polymeras
inhibit
compar
earlier
benzothiadiazin
analogu
effect
pyrrol
ring
quinolon
posit
keep
constant
swap
benzothiadiazin
nucleu
benzisothiazol
diazaphosphinin
explor
inhibitori
effici
comprehens
review
polymeras
inhibitor
previous
mention
da
et
al
depict
fig
new
set
heterocycl
small
molecul
nonnucleosid
agent
hcv
polymeras
identifi
combin
high
throughput
screen
ht
structurebas
drug
design
sbdd
approach
lead
modif
improv
hit
analogu
succeed
exert
potent
class
acryalamid
deriv
polymeras
inhibitor
present
fig
diketoacid
mecano
acid
test
inhibitor
hcv
polymeras
later
convert
dihydroxypyrimidinecarboxyl
acid
structur
optim
led
thiophen
deriv
potent
hcv
inhibitor
ht
base
assay
seri
librari
hcv
polymeras
offer
prolin
lnike
sulfonamid
ic
mm
found
select
toward
hcv
compar
polymeras
sar
studi
lead
optim
protocol
afford
hydroxi
deriv
ic
nm
potent
polymeras
inhibitor
identifi
hit
antivir
nacylpyrolidin
librari
afford
clinic
candid
hcv
infect
discov
ht
screen
ht
assay
hcv
polymeras
identifi
seri
rhodanin
analogu
promis
antivir
agent
optim
chloro
substitut
essenti
effici
benzodiazepin
antipsychot
scaffold
target
polymeras
scrutin
via
sbbd
platform
experi
antihcv
agent
palm
site
amid
base
inhibitor
includ
anthranalamid
nicotinamid
benzamid
illustr
fig
comprehens
literatur
divers
scaffold
hcv
polymeras
inhibitor
review
sofia
et
al
mechan
behind
bind
nonnucleosid
inhibitor
block
gtp
activ
within
thumb
site
hcv
polymeras
respect
aspect
varieti
heterocycl
small
molecul
test
polymeras
inhibit
capabl
among
benzimidazol
indol
thienopyrrol
pyrrazol
pteridin
quinoxolin
benzoxazapinoindol
benzodiazepinoindol
indol
sulfonamid
auron
deriv
report
signific
polymeras
inhibitori
activ
potent
among
thumb
inhibitor
enter
clinic
trial
molecular
level
interact
alli
biolog
profil
present
sofia
et
al
precis
molecular
structur
hcv
inhibitor
shown
fig
precis
role
thumb
ii
site
inhibitor
investig
small
heterocycl
agent
includ
dihydropyron
pibrentasvir
novel
pangenotyp
hepat
c
viru
hcv
inhibitor
exhibit
genotyp
ec
rang
pm
concentr
combin
pibrentasvir
class
hcv
inhibitor
yield
synergist
inhibitori
effect
hcv
replic
summari
pibrentasvir
turn
next
gener
hcv
inhibitor
evidenc
antihcv
activ
pangenotyp
velpatasvir
demonstr
potenc
genotyp
ic
av
pm
also
repress
three
mutat
form
without
alter
inhibitori
concentr
ic
av
pm
wherea
elev
inhibitori
level
samatasvir
ic
pm
genotyp
except
investig
ravidasvir
ic
pm
also
similar
analogu
samatasvir
phase
ii
trial
phase
ii
trial
compound
depict
fig
indol
analogu
bi
ec
nm
discov
potent
hcv
polymeras
thumb
pocket
inhibitor
pharmacokinet
profil
respect
clearanc
compound
low
later
clinic
investig
halt
genotox
clinic
candid
bi
reduc
structur
alter
ideolog
afford
nongenotox
hcv
thumb
site
inhibitor
ec
nm
preclin
investig
potent
drug
candid
beclabuvir
ec
nm
appear
safe
human
use
approv
hcv
treatment
japan
beclabuvir
base
ec
nm
fluro
compound
advanc
clinic
trial
repres
structur
provid
fig
benzofuron
group
substanc
enter
clinic
trial
display
prerequisit
hcv
inhibit
pharmacokinet
profil
combin
therapi
antihcv
agent
interferon
studi
due
liver
toxic
concern
abandon
trial
ec
nm
potenc
compound
increas
fold
modifi
aliphat
alcohol
boron
acid
ec
nm
result
structur
success
inhibit
mutat
hcv
isoform
addit
replac
oxazinoindol
linear
aryl
ring
provid
pan
hcv
inhibitor
ec
nm
clinic
candid
improvis
oral
bioavail
pharmacokinet
benzofuron
clinic
investig
hcv
candid
shown
fig
introduct
hetero
atom
posit
benzofuron
benzofuron
ring
categori
antihcv
agent
led
anoth
seri
potent
hcv
inhibitor
new
seri
clinic
agent
among
ec
nm
becom
ineffect
stage
phase
due
microcrystal
problem
toxicolog
studi
second
gener
pan
hcv
polymeras
inhibitor
e
genotyp
develop
modifi
addit
deuterium
group
observ
effici
metabol
stabil
escal
hcv
enzym
inhibit
ec
nm
nonnucleotid
palm
site
inhibitor
dasabuvir
approv
treatment
hcv
infect
safe
administ
antihcv
agent
chemic
structur
provid
fig
sixmemb
cyclic
unsatur
ester
share
chemic
physic
properti
reminisc
alken
aromat
compound
highli
abund
bacteria
microbi
plant
insect
anim
system
take
part
mani
differ
type
biolog
process
key
biosynthet
intermedi
metabolit
deriv
util
precursor
product
biolog
signific
compound
pheromon
achymotrypsin
numer
review
exist
microbi
secondari
metabolit
fungi
wide
rang
antifung
cytotox
neurotox
phytotox
agent
investig
respect
antitumor
hiv
proteas
inhibit
qualiti
enlighten
medicin
import
therefor
previous
scrutin
skeleton
design
comput
aid
structur
explor
synthesi
pyranin
base
new
carboxamid
analogu
discoveri
antivir
drug
candid
plausibl
approach
scaffold
exist
potent
antihcv
agent
sketch
fig
case
new
acut
infect
rais
everi
year
mortal
rate
chronic
hcv
infect
distress
sever
nation
mutat
hcv
viral
strain
immun
respons
hcv
diseas
alleg
foremost
rate
limit
issu
ongo
antihcv
therapi
precis
inexpens
pangenotyp
direct
act
antivir
requir
earliest
context
sever
direct
act
hcv
rna
polymeras
inhibitor
employ
essenti
antivir
util
either
blend
pegifn
rbv
mix
daa
without
interferon
regimen
similarli
advanc
dynam
antiretrovir
hiv
treatment
antihcv
therapi
would
requir
combat
pangenotyp
hcv
viral
burden
process
deliv
sever
hcv
polymeras
inhibitor
includ
nucleosid
nonnucleosid
base
inhibitor
new
class
nucleosid
hcv
inhibitor
exhibit
promis
antihcv
regimen
human
clinic
trial
develop
nucleotid
prodrug
deliv
nucleosid
hepatocyt
anoth
power
approach
nucleosid
drug
discoveri
use
treat
liver
associ
hcv
infect
remark
nucleosid
monophosph
prodrug
enter
clinic
improv
indic
extraordinari
adequaci
overal
aspect
current
review
might
provid
signific
inform
exist
antihcv
treatment
strategi
develop
target
base
antihcv
agent
clinic
agent
